Jump to content

Talk:Cancer vaccine

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Drug Development

[edit]

I don't get this:

Do not randomize antigen plus adjuvant versus adjuvant alone. The goal is to establish clinical benefit of the immunotherapy (i.e.,adjuvanted vaccine) over the standard of care, not over standard of care plus adjuvant. The adjuvant may have a low-level clinical effect that would skew the statistical powering of the trial, increasing the chances of a false negative.

Suppose the adjuvant has a clinical effect, but the vaccine is ineffective. You'd get improvement in the treatment group, and attribute it to the vaccine, even though the vaccine is ineffective. Right? Nbauman (talk) 17:54, 23 January 2009 (UTC)[reply]

Almost. I read it as the 'adjuvant alone' group is the control (presumably to allow blinding) rather than part of the treatment group. Hence if the adjuvant by itself has a benefit then the vaccine will have to have a stronger benefit to 'pass' the trial. Rod57 (talk) 07:28, 12 August 2009 (UTC)[reply]

(I can't get access to the original journal and read the article.)

More generally, I think this section may be too much of a technical checklist. Nbauman (talk) 17:54, 23 January 2009 (UTC)[reply]

Yes, let's just delete this Recommendations section. It does not seem relevant/specific enough or worth reading. - Rod57 (talk) 14:01, 10 July 2016 (UTC)[reply]

Restructure

[edit]

Could restructure/split to show which are autologous therapeutic cancer vaccines and which are not. Rod57 (talk) 22:31, 18 October 2010 (UTC)[reply]

NIH has an excellent description of cancer vaccines. It would make this page much stronger. I added DNDN's Neuvenge vaccine and the DNDN stock symbol. These synbols needs to be added to the other pharm companies. Also, see Coley's Toxins for a long history on immunotherapy. That needs to be a part of the history section.Bgordski (talk) 06:57, 14 December 2010 (UTC)[reply]

[edit]

I recently fixed a link (used to go to different types of cancer; now goes to Types of cancer) in the main section, but it seems sort-of out of place to me. Types of cancer are, of course, important in an article about a cancer vaccine, but should the link not have some sort of introduction/explanation? BobFijiwinkle (talk) 22:13, 3 April 2011 (UTC)[reply]

Resource in current SciAm

[edit]

A New Ally against Cancer; The FDA recently okayed the first therapeutic cancer vaccine, and other drugs that enlist the immune system against tumors are under study by Eric von Hofe in September 30, 2011 issue of Scientific American. 97.87.29.188 (talk) 19:07, 27 September 2011 (UTC)[reply]

Definition and content mismatch - rename

[edit]

Def/overview is slightly confused whether its about cancer prevention or treatment, the rest of the article seems to talk about cancer treatment which seems also to reflect use in publications. Hence I think this article should concentrate solely on cancer treatment and link cancer immunoprevention for prevention. Richiez (talk) 22:02, 1 February 2012 (UTC)[reply]

I agree. It's still almost totally about therapeutic cancer vaccines and cancer immunotherapies. Perhaps we should rename this page to therapeutic cancer vaccine and give it a hatnote to cancer immunoprevention (cancer vaccine could redirect to this renamed article). Rename ? - Rod57 (talk) 13:55, 10 July 2016 (UTC)[reply]
I've tried to add the hatnote (after first line of Intro) - perhaps it should be at the very top ? - Rod57 (talk) 14:35, 10 July 2016 (UTC)[reply]

There is something wrong with the last link in the article. It points to an erroneous web archive link. — Preceding unsigned comment added by 109.247.173.128 (talk) 16:52, 27 April 2022 (UTC)[reply]

pipleine-ish section

[edit]

mostly unsourced or sourced to SPS or primary sources; includes dead things and current things. tables like this are tempting to create but a nightmare to maintain and generally are OR collections.

Vaccine candidates

Most of the cancer vaccines in development address specific cancer types and are therapeutic vaccines. These include:

Vaccine candidates
Developer Vaccine Notes
Aduro GVAX formerly developed by Cell Genesys
Advaxis[1] ADXS11-001, ADXS31-001, ADXS31-164
ALVAC-CEA vaccine
Avax Technologies AC Vaccine
Amgen talimogene laherparepvec
Biovest International BiovaxID Phase III
Bavarian Nordic[2] Prostvac
Celldex Therapeutics CDX110, rindopepimut), CDX1307 and CDX1401
The Center of Molecular Immunology, CimaVax-EGF lung cancer
CureVac[3] CV9104 mRNA-based cancer immunotherapy; CV9104 is currently being evaluated in an international Phase 2b trial in patients with castration-resistant prostate cancer.[3]
Dendreon Corp DNDN) Neuvenge HER2/neu expressing cancers such as Breast, Bladder, colon, Ovarian),[4]
Galena Biopharma NeuVax
Generex Biotechnology (Antigen Express) Ae-37)
Geron Corporation GRNVAC1
GlaxoSmithKline Melanoma treatment targeting MAGE-A3
GlobeImmune[5][6] Tarmogens, GI-4000, GI-6207, GI-6301)[7]
Heat Biologics ImPACT Therapy NSCLC and other cancers
Immatics biotechnologies IMA901 Renal cancer)[8]
Immunitor hepcortespenlisimut-L (Hepko-V5) Trials of an oral cancer vaccine[9][10] A Phase 3 trial in hepatocellular carcinoma was first made public in September 2014.[11]
Merck Stimuvax in 2009, is starting phase III trials of for breast cancer.[12] It had promising results from a phase IIB trial for inoperable lung cancer.
Northwest Biotherapeutics[13] DCVax-L, DCVax-Direct, DCVax Prostate Phase 3 trial for glioblastoma multiforme
Panacela Labs, Inc.[15] CBLI MOBILAN Adenovirus-based treatment inducing immune response. Final stage of preclinical development.
Prima BioMed LTD Cvac Ovarian cancer in phase III.[16]
Regeneus Ltd RGSH4K An autologous cancer immunotherapy which uses the tumor as source material for the vaccine - in phase I
Scancell Holdings, SCIB1
OncoPep, Inc NCT01758328, PVX-410 (Multi-peptide vaccine) in a phase I/II trial[17] to treat smoldering multiple myeloma.[18]

References

  1. ^ "Updated Advaxis Phase I Survival Data Indicates Long-Term Immune Protection". Medical News Today. 4 October 2009. Retrieved 4 February 2015.
  2. ^ "Bavarian Nordic".
  3. ^ a b "Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer".
  4. ^ "Dendreon Presents Integrated Analysis of Clinical Data from Neuvenge Trials at Chemotherapy Foundation Symposium - Drugs.com MedNews".
  5. ^ ""GlobeImmune Initiates Phase 2 Trial for Pancreas Cancer" 2006". Retrieved 6 July 2017.
  6. ^ "GlobeImmune Raises $17.5M in Series E Financing - GEN News Highlights".
  7. ^ "Search of: globeimmune - List Results - ClinicalTrials.gov".
  8. ^ "Immatics Raises Nearly €54M to Take Lead Therapeutic Cancer Vaccine into Phase III - GEN News Highlights - GEN".
  9. ^ "FDA Orphan designation". Retrieved 6 July 2017.
  10. ^ Tarakanovskaya, Marina G; Chinburen, Jigjidsuren; Batchuluun, Purev; Munkhzaya, Chogsom; Purevsuren, Genden; Dandii, Dorjiin; Hulan, Tsogkhuu; Oyungerel, Dandii; Kutsyna, Galyna A; Reid, Alan A; Borisova, Vika; Bain, Allen I; Jirathitikal, Vichai; Bourinbaiar, Aldar S (12 April 2017). "Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L". Journal of Hepatocellular Carcinoma. 4: 59–69. doi:10.2147/JHC.S122507. ISSN 2253-5969. PMID 5396941.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  11. ^ Clinicaltrials.gov https://clinicaltrials.gov/show/NCT02232490
  12. ^ Burger, Ludwig (June 22, 2009). "UPDATE 2-Merck to test stimuvax cancer drug in Phase III". Reuters.
  13. ^ "DCVax ® Technology - Northwest Biotherapeutics".
  14. ^ "OncoTherapy Science, Inc".
  15. ^ "Cleveland Bio Labs - Develop innovative drugs to treat cancer". www.cbiolabs.com. Retrieved 6 July 2017.
  16. ^ "How long before CVac, a new treatment for ovarian cancer, is available in the UK?". The Daily Telegraph. London. February 10, 2012.
  17. ^ "Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma - Full Text View - ClinicalTrials.gov".
  18. ^ "Multiple Myeloma".

-- Jytdog (talk) 20:56, 6 November 2017 (UTC)[reply]

Merger proposal

[edit]

I suggest merging Tumor antigen vaccine into Cancer vaccine as I understand they seem identical to me. A455bcd9 (talk) 09:36, 10 January 2022 (UTC)[reply]

  checkY Merger complete. Klbrain (talk) 08:08, 14 August 2022 (UTC)[reply]

The moleculer basis of cancer in young adults

[edit]

Article Research Ukayclare001 (talk) 21:41, 16 November 2023 (UTC)[reply]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Cancer_vaccine&oldid=1200593628"